|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suzuki H, Ono H, Hirasawa T, Takeuchi Y,
Ishido K, Hoteya S, Yano T, Tanaka S, Toya Y, Nakagawa M, et al:
Long-term survival after endoscopic resection for gastric cancer:
Real-world evidence from a multicenter prospective cohort. Clin
Gastroenterol Hepatol. 21:307–318.e2. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hiki N, Katai H, Mizusawa J, Nakamura K,
Nakamori M, Yoshikawa T, Kojima K, Imamoto H, Ninomiya M, Kitano S,
et al: Long-term outcomes of laparoscopy-assisted distal
gastrectomy with suprapancreatic nodal dissection for clinical
stage I gastric cancer: A multicenter phase II trial (JCOG0703).
Gastric Cancer. 21:155–161. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Janjigian YY, Shitara K, Moehler M,
Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T,
Campos Bragagnoli A, et al: First-line nivolumab plus chemotherapy
versus chemotherapy alone for advanced gastric, gastro-oesophageal
junction, and oesophageal adenocarcinoma (CheckMate 649): A
randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC,
Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, et al:
Nivolumab plus chemotherapy versus placebo plus chemotherapy in
patients with HER2-negative, untreated, unresectable advanced or
recurrent gastric or gastro-oesophageal junction cancer
(ATTRACTION-4): A randomised, multicentre, double-blind,
placebo-controlled, phase 3 trial. Lancet Oncol. 23:234–247. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thomassen I, van Gestel YR, van Ramshorst
B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE and de Hingh IH:
Peritoneal carcinomatosis of gastric origin: A population-based
study on incidence, survival and risk factors. Int J Cancer.
134:622–628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishigami H, Fujiwara Y, Fukushima R,
Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y,
Amagai K, et al: Phase III trial comparing intraperitoneal and
intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in
patients with gastric cancer with peritoneal metastasis: PHOENIX-GC
trial. J Clin Oncol. 36:1922–1929. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lauren P: THE Two Histological Main Types
Of Gastric Carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okumura S, Kaido T, Hamaguchi Y, Fujimoto
Y, Masui T, Mizumoto M, Hammad A, Mori A, Takaori K and Uemoto S:
Impact of preoperative quality as well as quantity of skeletal
muscle on survival after resection of pancreatic cancer. Surgery.
157:1088–1098. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iwai N, Okuda T, Oka K, Sakagami J, Harada
T, Ohara T, Hattori C, Taniguchi M, Sakai H, Hara T, et al:
Depletion of psoas muscle mass after systemic chemotherapy is
associated with poor prognosis in patients with unresectable
pancreatic cancer. Cancers (Basel). 13:38602021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nishina T, Boku N, Gotoh M, Shimada Y,
Hamamoto Y, Yasui H, Yamaguchi K, Kawai H, Nakayama N, Amagai K, et
al: Randomized phase II study of second-line chemotherapy with the
best available 5-fluorouracil regimen versus weekly administration
of paclitaxel in far advanced gastric cancer with severe peritoneal
metastases refractory to 5-fluorouracil-containing regimens
(JCOG0407). Gastric Cancer. 19:902–910. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakajima TE, Yamaguchi K, Boku N, Hyodo I,
Mizusawa J, Hara H, Nishina T, Sakamoto T, Shitara K, Shinozaki K,
et al: Randomized phase II/III study of 5-fluorouracil/l-leucovorin
versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to
patients with severe peritoneal metastases of gastric cancer
(JCOG1108/WJOG7312G). Gastric Cancer. 23:677–688. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chau I, Norman AR, Cunningham D, Waters
JS, Oates J and Ross PJ: Multivariate prognostic factor analysis in
locally advanced and metastatic esophago-gastric cancer-pooled
analysis from three multicenter, randomized, controlled trials
using individual patient data. J Clin Oncol. 22:2395–2403. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee J, Lim T, Uhm JE, Park KW, Park SH,
Lee SC, Park JO, Park YS, Lim HY, Sohn TS, et al: Prognostic model
to predict survival following first-line chemotherapy in patients
with metastatic gastric adenocarcinoma. Ann Oncol. 18:886–891.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim SY, Yoon MJ, Park YI, Kim MJ, Nam BH
and Park SR: Nomograms predicting survival of patients with
unresectable or metastatic gastric cancer who receive combination
cytotoxic chemotherapy as first-line treatment. Gastric Cancer.
21:453–463. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takahari D, Boku N, Mizusawa J, Takashima
A, Yamada Y, Yoshino T, Yamazaki K, Koizumi W, Fukase K, Yamaguchi
K, et al: Determination of prognostic factors in Japanese patients
with advanced gastric cancer using the data from a randomized
controlled trial, Japan clinical oncology group 9912. Oncologist.
19:358–366. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takahari D, Mizusawa J, Koizumi W, Hyodo I
and Boku N: Validation of the JCOG prognostic index in advanced
gastric cancer using individual patient data from the SPIRITS and
G-SOX trials. Gastric Cancer. 20:757–763. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma T, Wu Z, Zhang X, Xu H, Feng Y, Zhang
C, Xie M, Yang Y, Zhang Y, Feng C and Sun G: Development and
validation of a prognostic scoring model for mortality risk
stratification in patients with recurrent or metastatic gastric
carcinoma. BMC Cancer. 21:13262021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Boku N, Yamamoto S, Fukuda H, Shirao K,
Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, et
al: Fluorouracil versus combination of irinotecan plus cisplatin
versus S-1 in metastatic gastric cancer: A randomised phase 3
study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Namikawa T, Ishida N, Tsuda S, Fujisawa K,
Munekage E, Iwabu J, Munekage M, Uemura S, Tsujii S, Tamura T, et
al: Prognostic significance of serum alkaline phosphatase and
lactate dehydrogenase levels in patients with unresectable advanced
gastric cancer. Gastric Cancer. 22:684–691. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Murakami Y, Saito H, Shimizu S, Kono Y,
Shishido Y, Miyatani K, Matsunaga T, Fukumoto Y and Fujiwara Y:
Neutrophil-to-lymphocyte ratio as a prognostic indicator in
patients with unresectable gastric cancer. Anticancer Res.
39:2583–2589. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Templeton AJ, McNamara MG, Šeruga B,
Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106:dju1242014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iwai N, Okuda T, Sakagami J, Harada T,
Ohara T, Taniguchi M, Sakai H, Oka K, Hara T, Tsuji T, et al:
Neutrophil to lymphocyte ratio predicts prognosis in unresectable
pancreatic cancer. Sci Rep. 10:187582020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shimura T, Toden S, Kandimalla R, Toiyama
Y, Okugawa Y, Kanda M, Baba H, Kodera Y, Kusunoki M and Goel A:
Genomewide expression profiling identifies a novel miRNA-based
signature for the detection of peritoneal metastasis in patients
with gastric cancer. Ann Surg. 274:e425–e434. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Emoto S, Ishigami H, Yamashita H,
Yamaguchi H, Kaisaki S and Kitayama J: Clinical significance of
CA125 and CA72-4 in gastric cancer with peritoneal dissemination.
Gastric Cancer. 15:154–161. 2012. View Article : Google Scholar : PubMed/NCBI
|
